NCT06840288

Brief Summary

To aggregate, integrate, and analyze data facilitating the study of MD Anderson patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P75+ for all trials

Timeline
129mo left

Started Feb 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress10%
Feb 2025Dec 2036

First Submitted

Initial submission to the registry

February 17, 2025

Completed
2 days until next milestone

Study Start

First participant enrolled

February 19, 2025

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 21, 2025

Completed
9.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2034

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2036

Last Updated

December 18, 2025

Status Verified

December 1, 2025

Enrollment Period

9.9 years

First QC Date

February 17, 2025

Last Update Submit

December 10, 2025

Conditions

Thoracic Tumors

Outcome Measures

Primary Outcomes (1)

  • To aggregate, integrate, and analyze data facilitating the study of MD Anderson patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.

    Through study completion, an average of 1 year.

Study Arms (1)

Small Thoracic Tumors

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

MD Anderson Cancer Center

You may qualify if:

  • Patients with peripheral lung tumors (primary or metastatic) that have been or will be ablated via robotic bronchoscopy.

You may not qualify if:

  • Patients with planned bronchoscopic ablations of peripheral lung tumors that were aborted for technical reasons (ablation was not completed).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MD Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

Study Officials

  • Roberto F Casal, MD

    Prinicipal Investigator

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Roberto F Casal, MD

CONTACT

(713) 792-6238rfcasal@mdanderson.org

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 17, 2025

First Posted

February 21, 2025

Study Start

February 19, 2025

Primary Completion (Estimated)

December 31, 2034

Study Completion (Estimated)

December 31, 2036

Last Updated

December 18, 2025

Record last verified: 2025-12

Locations

US(1)